Financial statements Financial statements of the company: Notes to the company financial statements of Diageo plc DIAGEO ANNUAL REPORT 2018 153 6.
Shareholders funds The movement in the net surplus for the two years ended a Merger reserve 30 June 2018, for all UK post employment plans for which the On the acquisition of a business, or of an interest in an associate, fair company is the sponsor, is as follows: values, reflecting conditions at the date of acquisition, are attributed to the net assets acquired.
Where merger relief is applicable under Net Plan Plan deficit the UK Companies Acts, the difference between the fair value of the assets liabilities surplus business acquired and the nominal value of shares issued as purchase million million million consideration is treated as a merger reserve.
At 30 June 2016 6,047 6,193 146 Charge before taxation 166 233 67 b Own shares Other comprehensive income loss 817 597 220 At 30 June 2018 own shares comprised 4 million ordinary shares Contributions by group companies 99 99 held by employee share trusts 2017 5 million: 2016 7 million : Employee contributions 1 1 222 million ordinary shares repurchased and held as treasury shares 2017 222 million: 2016 223 million : and 12 million ordinary shares Benefits paid 341 341 held as treasury shares for hedging share scheme grants 2017 At 30 June 2017 6,789 6,683 106 14 million: 2016 14 million.
Charge before taxation 166 215 49 In the year ended 30 June 2018 the company purchased Other comprehensive income 247 359 606 58.9 million ordinary shares for a cost of 1,507 million including Contributions by group companies 94 94 9 million of transaction costs through a share buyback programme.
Employee contributions 1 1 The shares purchased under the share buyback programme were Benefits paid 505 505 cancelled.
At 30 June 2018 6,792 6,035 757 As at 30 June 2017 the Guinness Ireland Group Pension Scheme held 22,807 ordinary shares in Diageo plc.
The net surplus for the UK post employment plans of 757 million Information on movements in own shares is provided in note 17 c 2017 106 million for which the company is a sponsor comprises to the consolidated financial statements.
funded plans of 858 million 2017 214 million disclosed as part c Retained earnings of non-current assets and unfunded liabilities of 101 million 2017 4,185 million 2017 4,644 of retained earnings is available for the 108 million disclosed as part of non-current liabilities.
payment of dividends, or purchases of own shares.
Additional information on the UK post employment plans and the principal risks and assumptions applicable is disclosed in note 13 10.
Post balance sheet event to the consolidated financial statements.
On 25 July 2018 the Board resolved to delegate to a committee of the Board a decision in respect of a potential share buyback programme 7.
Provisions of up to 2 billion in the year ending 30 June 2019.
It is anticipated Thalidomide Other Total that the committee will make a decision on the matter at a meeting million million million to be held on 26 July 2018.
At 30 June 2017 208 208 Provisions charged during the year 2 2 Provisions utilised during the year 11 11 Unwinding of discounts 6 6 At 30 June 2018 203 2 205 The companys commitment to the UK Thalidomide Trust is discounted and will be utilised over the period of the commitment up to 2037.
At 30 June 2018 13 million 2017 17 million of provision is current and 192 million 2017 191 million is non-current.
Financial guarantees The company has guaranteed certain borrowings of subsidiaries which at 30 June 2018 amounted to 9,177 million 2017 8,099 million.
The company has also provided irrevocable guarantees relating to the liabilities of certain of its Irish and Dutch subsidiaries.
In addition, the company has provided a guarantee to the Guinness Ireland Group Pension Scheme.
The Directors do not expect the company to be liable for any legal obligation in respect of these financial guarantee agreements, and they have been recognised at nil fair value.
